Literature DB >> 19307362

Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells.

Béatrice Marquez1, Nancy E Caceres, Marie-Paule Mingeot-Leclercq, Paul M Tulkens, Françoise Van Bambeke.   

Abstract

Ciprofloxacin, the most widely used totally synthetic antibiotic, is subject to active efflux mediated by a MRP-like transporter in wild-type murine J774 macrophages. To identify the transporter among the seven potential Mrps, we used cells made resistant to ciprofloxacin obtained by long-term exposure to increasing drug concentrations (these cells show less ciprofloxacin accumulation and provide a protected niche for ciprofloxacin-sensitive intracellular Listeria monocytogenes). In the present paper, we first show that ciprofloxacin-resistant cells display a faster efflux of ciprofloxacin which is inhibited by gemfibrozil (an unspecific MRP inhibitor). Elacridar, at a concentration known to inhibit P-glycoprotein and breast cancer resistance protein (BCRP), only slightly increased ciprofloxacin accumulation, with no difference between resistant and wild-type cells. Analysis at the mRNA (real-time PCR) and protein (Western blotting) levels revealed an overexpression of Mrp2 and Mrp4. Mrp4 transcripts, however, were overwhelmingly predominant (45% [wild-type cells] to 95% [ciprofloxacin-resistant cells] of all Mrp transcripts tested [Mrp1 to Mrp7]). Silencing of Mrp2 and Mrp4 with specific small interfering RNAs showed that only Mrp4 is involved in ciprofloxacin transport in both ciprofloxacin-resistant and wild-type cells. The study therefore identifies Mrp4 as the most likely transporter of ciprofloxacin in murine macrophages but leaves open a possible common upregulation mechanism for both Mrp4 and Mrp2 upon chronic exposure of eukaryotic cells to this widely used antibiotic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19307362      PMCID: PMC2687251          DOI: 10.1128/AAC.01428-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.

Authors:  Axel Priebsch; Franziska Rompe; Holger Tönnies; Petra Kowalski; Pawel Surowiak; Alexandra Stege; Verena Materna; Hermann Lage
Journal:  Oligonucleotides       Date:  2006

Review 2.  Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.

Authors:  Roger G Deeley; Christopher Westlake; Susan P C Cole
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

3.  Glutathione export during apoptosis requires functional multidrug resistance-associated proteins.

Authors:  Christine L Hammond; Rosemarie Marchan; Suzanne M Krance; Nazzareno Ballatori
Journal:  J Biol Chem       Date:  2007-03-20       Impact factor: 5.157

Review 4.  MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance.

Authors:  Hermann Lage
Journal:  Curr Drug Targets       Date:  2006-07       Impact factor: 3.465

Review 5.  Multidrug resistance-associated proteins 3, 4, and 5.

Authors:  Piet Borst; Cornelia de Wolf; Koen van de Wetering
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

6.  Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm.

Authors:  Nobuhito Ono; Ingrid Van der Heijden; George L Scheffer; Koen Van de Wetering; Elizabeth Van Deemter; Marcel De Haas; Arjan Boerke; Bart M Gadella; Dirk G De Rooij; Jacques J Neefjes; Tom A M Groothuis; Lauran Oomen; Lenny Brocks; Toshihisa Ishikawa; Piet Borst
Journal:  Biochem J       Date:  2007-08-15       Impact factor: 3.857

Review 7.  Fluoroquinolone efflux mediated by ABC transporters.

Authors:  Ana I Alvarez; Miriam Pérez; Julio G Prieto; Antonio J Molina; Rebeca Real; Gracia Merino
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

Review 8.  Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules.

Authors:  Frans G M Russel; Jan B Koenderink; Rosalinde Masereeuw
Journal:  Trends Pharmacol Sci       Date:  2008-03-18       Impact factor: 14.819

9.  Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB.

Authors:  Kenji Negoro; Yukio Yamano; Kazuaki Fushimi; Kengo Saito; Ken Nakatani; Masashi Shiiba; Hidetaka Yokoe; Hiroki Bukawa; Katsuhiro Uzawa; Takeshi Wada; Hideki Tanzawa; Shigeyuki Fujita
Journal:  Int J Oncol       Date:  2007-06       Impact factor: 5.650

10.  Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance.

Authors:  Yusuf Baran; Bala Gür; Pelin Kaya; Ali Uğur Ural; Ferit Avcu; Ufuk Gündüz
Journal:  Hematology       Date:  2007-12       Impact factor: 2.269

View more
  9 in total

1.  Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).

Authors:  I S Haslam; J A Wright; D A O'Reilly; D J Sherlock; T Coleman; N L Simmons
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

Review 2.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

Review 3.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

4.  Investigation of the Importance of Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) in the Active Efflux of Anionic Drugs Across the Blood-Brain Barrier.

Authors:  Kayoko Kanamitsu; Hiroyuki Kusuhara; John D Schuetz; Kenji Takeuchi; Yuichi Sugiyama
Journal:  J Pharm Sci       Date:  2017-04-27       Impact factor: 3.534

5.  Effect of Multi Drug Resistance Protein 4 (MRP4) Inhibition on the Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Normal and Rats with LPS-Induced Inflammation.

Authors:  V Gangadhara N V Prasad; Satyanarayana Achanta; Yathiraja Rao Tammineni; Gopala Reddy Alla; Madhava Rao Thirtham; G S Rao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

6.  Pharmacological characterization of 7-(4-(Piperazin-1-yl)) ciprofloxacin derivatives: antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity.

Authors:  Béatrice Marquez; Vincent Pourcelle; Coralie M Vallet; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Jacqueline Marchand-Bruynaert; Françoise Van Bambeke
Journal:  Pharm Res       Date:  2013-12-05       Impact factor: 4.200

7.  Characterization of Abcc4 gene amplification in stepwise-selected mouse J774 macrophages resistant to the topoisomerase II inhibitor ciprofloxacin.

Authors:  Béatrice Marquez; Geneviève Ameye; Coralie M Vallet; Paul M Tulkens; Hélène A Poirel; Françoise Van Bambeke
Journal:  PLoS One       Date:  2011-12-05       Impact factor: 3.240

Review 8.  A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?

Authors:  Lorena Baietto; Silvia Corcione; Giovanni Pacini; Giovanni Di Perri; Antonio D'Avolio; Francesco Giuseppe De Rosa
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

9.  Analysis of the membrane proteome of ciprofloxacin-resistant macrophages by stable isotope labeling with amino acids in cell culture (SILAC).

Authors:  Nancy E Caceres; Maarten Aerts; Béatrice Marquez; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Bart Devreese; Françoise Van Bambeke
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.